Biotech Values

[DewDiligence]

EyeGate Pharma adds iontophoresis expert to SAB.

http://biz.yahoo.com/iw/070620/0268447.html

>>
EyeGate Pharma Appoints Richard Guy to Scientific Advisory Board and Announces Collaborative Research Agreement With University of Bath

Wednesday June 20, 8:30 am ET

WALTHAM, MA--(MARKET WIRE)--Jun 20, 2007 -- EyeGate Pharma, a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced that Richard Guy, Ph.D., a leading expert on iontophoretic drug delivery and Professor at the University of Bath, UK, has been appointed to EyeGate's Scientific Advisory Board.

Stephen From, President and Chief Executive Officer of EyeGate, commented, "Dr. Guy is one of the world's leading experts on dermal iontophoretic drug delivery. EyeGate is the first company to succeed in proof-of-concept studies using iontophoresis technology to safely deliver therapeutics to the eye. Our collaboration with Dr. Guy and his colleagues at the University of Bath will focus on determining the differences and similarities between dermatologic and ophthalmic iontophoretic drug delivery."

Dr. Richard Guy added, "Ocular iontophoretic drug delivery is not a new concept. It has taken nearly twenty years to perfect, but EyeGate is succeeding where others have failed. I believe that EyeGate's success is due to the fact that the technology was designed with ophthalmologists, and not merely an attempt to apply what's known about the skin to the eye. I look forward to working closely with Stephen and his team to expedite the commercialization of the EyeGate® II Delivery System."

Richard Guy received an M.A. in Chemistry from Oxford University and his Ph.D. in Pharmaceutical Chemistry from the University of London. He was a faculty member at the University of California, San Francisco, for 16 years, and Vice Chair of the Department of Biopharmaceutical Sciences for much of that time. Dr. Guy then served as Scientific Director of the Centre interuniversitaire de recherche et d'enseignement (Universities of Geneva and Lyon) and Professor in the Faculty of Sciences at the University of Geneva. In 2004, he became Professor of Pharmaceutical Sciences at the University of Bath and is currently Head of the Department of Pharmacy & Pharmacology. He remains an Adjunct Professor of Biopharmaceutical Sciences at UCSF. In 1994, Dr. Guy co-founded De Novo, Inc., a start-up company focused on the development of novel dermatological therapies.

Dr. Guy is an elected fellow of the Royal Society of Chemistry, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science. He was the first recipient of the Controlled Release Society's Young Investigator Award in 1988, the same year that he won the British Pharmaceutical Conference Science Award. Dr. Guy was awarded, for his work in iontophoresis, the Prix Applications Médicales de l'Electricité, by the Institut Electricité Santé, Paris, France. In 2000, Dr. Guy received the International Association for Pharmaceutical Technology (APV) Research Award for Outstanding Achievements in the Pharmaceutical Sciences.

About EyeGate Pharma

EyeGate Pharma was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was designed by ophthalmologists for ophthalmologists. This non-invasive system can be applied to safely deliver a wide range of therapeutics to both the anterior and posterior chambers of the eye. An 89-patient pilot study, using the Company's first-generation delivery device, demonstrated exceptional patient tolerance with a significant decrease in inflammatory markers and a concurrent increase in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe uveitis and other inflammatory ocular diseases. Clinical studies using the EyeGate® II Delivery System are planned for 2008. For more information please visit www.eyegatepharma.com.
<<